PG Research Update — June 20, 2026
Updated Thesis
The Procter & Gamble Company is a leading global consumer defensive company specializing in household and personal products with a strong portfolio across fabric care, baby and family care, beauty, health care, and grooming. The business quality is high, supported by a durable competitive moat from strong brands, consistent earnings growth, and prudent capital allocation emphasizing dividends and buybacks. The stock is fairly valued at a P/E of 21.51 and EV/EBITDA of 15.06, reflecting a quality compounder premium balanced against modest organic growth and tariff-related headwinds.
The investment grade as of this refresh is B — solid business quality. High-tier business, B-tier valuation with 10% upside to $165.39 fair value
Key Metrics at a Glance
- Revenue growth: +7.4% year over year
- Net margin: 19.2%
- Forward P/E: 21.5x
- Fair value upside: +10.0% to our estimate of $165
Current price: $150.38
These figures reflect our most recent data pull and are one input into a multi-factor valuation framework.
Our 12–18 Month Outlook
Quality companies held over a multi-year horizon benefit from compounding fundamentals and the patience to ride through short-term volatility. The Procter & Gamble Company remains in our covered universe with a solid-quality assessment. We update research when material data changes — earnings revisions, management shifts, or regime changes in valuation — not on every price fluctuation.
Long-term accumulation of quality businesses at fair or better prices is the core of the Patient Accumulator approach. Research updates like this one inform whether to add, hold, or wait for a better zone — not whether to react to short-term price moves.
[View full PG research →](/stocks/PG)